RE: Opinions13 Jul 2020 18:52
Dick,
Sorry to hear you are so negative, perhaps you could read through some of the informative posts and perhaps also look at Scancell's website:-
24 June 2020
Scancell Holdings plc
(“Scancell” or the “Company”)
New publication highlights potential of Modi-1 for hard to treat cancers
Modi-1 Phase 1/2 trial expected to start in H1 2021
Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer,
is pleased to announce the publication of a peer-reviewed research paper in the Journal for
ImmunoTherapy of Cancer entitled: “Combination vaccine based on citrullinated vimentin and enolase
peptides induces potent CD4-mediated anti-tumor responses”.1 The Company also provides an update
on current progress and future plans for a Phase 1/2 clinical trial in patients with solid tumours including
triple negative breast cancer, ovarian cancer, renal cancer and head and neck cancer.
Scancell’s Moditope® platform represents a completely new class of potent and selective
immunotherapy agents based on stress-induced post-translational modifications (siPTM) such as
citrullination. The publication describes the first Moditope® vaccine, Modi-1, and its ability to stimulate
potent T cell responses that translate into tumour protection in melanoma and ovarian cancer models.
The responses were mediated by CD4 T cells and were also able to protect against a second challenge
of the tumour confirming the induction of a memory response. The paper also confirms that conjugating
the Modi-1 citrullinated peptides to the toll-like receptor-stimulating adjuvant AMPLIVANT®, previously
licensed from ISA Pharmaceuticals, allows the therapeutic dose to be reduced by up to 100-fold. The
full abstract is detailed below.
In January 2020, the Company provided an update on progress towards initiating the Modi-1 Phase 1/2
clinical trial. This has been advanced further with successful completion of GMP drug substance
manufacture for all three of the conjugates that comprise the Modi-1 product. Importantly, the technical
challenges reported in January concerning one of the peptide components have been successfully
resolved, enabling progression to GMP drug product manufacture and formulation of clinical supplies
in Q3 2020.
Formal regulatory-compliant toxicity studies have now been completed, with no evidence of any local
or systemic toxicities being reported. In addition to the Scientific Advice meeting held with the PaulEhrlich-Institut regulatory authority in 2019, a further successful meeting was held with the UK
Medicines and Healthcare products Regulatory Agency in February 2020. The Company continues to
progress the necessary processes and documentation required for regulatory submission to start the
planned clinical study in the UK in the first half of 2021.
Professor Lindy Durrant, Chief Scientific Officer of Scancell, commented:
“These data further validate the unique mode of action, and long-term prote
Sign In
Follow the stocks
